A normal blood draw is enough to help your doctor detect and classify suspected or diagnosed cancer at various stages of the disease.Our services
If you already have a cancer diagnosis, you and your treating physician should agree that iCellate's service OncoMate® is right for you.
GeneMate® and CellMate® do not require prior physician consultation.
By way of a blood sample, iCellate detects any potential tumor cells or tumor fragments which are then analyzed in iCellate's lab in Stockholm.
Cancer in the family can cause great, and sometimes unnecessary, concern. iCellate analyzes the DNA in a simple saliva sample, assesses your hereditary risk for cancer, and suggests preventative action.
iCellate’s genetic cancer evaluation, using circulating tumor DNA (ctDNA), provides detailed genetic tumor information which may reveal targeted treatment options.
Early detection is important for effective cancer treatment. iCellate can, even before symptoms occur, detect the spreading cancer cells through a simple blood test.
Cancer originates from gene mutations in cells. Exposures or habits such as smoking or poor eating habits are well-known risk factors. Mutations may also be inherited.
Of all cancer diagnoses, about 5-10% are hereditary. The risk of developing cancer may be reduced if you take action in time.
If several people in your family have had cancer, especially at an early age, you may want to assess your risk level through our inherited cancer test.
iCellate’s blood biopsies complement the established methods in general healthcare. These new methods are not yet standard in today’s medical care.
iCellate is commited to providing patients with the best possible care through continuous iteration, enhancement and validation of its services.
If cancer is detected early, it is much more likely to be cured. Therefore, it is important that the cancer care of the future adopts methods for early detection.
The number of cancer diagnoses is increasing every year. According to the World Health Organization, 70% more people will be diagnosed with cancer in 2030 compared to today.
iCellate's unique method of testing for circulating tumor cells (CTCs) in the blood is a universal solution for detecting most cancers early. This has been demonstrated in two recent screening studies that can be read here.
Roche financed the development of the first prototypes leading to the instrument IsoPic™ and contributed to R&D know-how in the early phases.
iCellate entered strategic partnerships with some key affiliates, leading to new discoveries in cell detection automation.
The AFA grant resulted in a more robust way to handle CTCs while keeping DNA intact and novel techniques to extract and amplify DNA from a single cell.
iCellate was awarded the ”Vinn verifiering” by Vinnova that resulted in early verification of the CTC isolation technique.